Pharmaceutical Innovation and Drug Policy: The Case of the 1984 Hatch-Waxman Act
Benjamin M Blau, Joshua Lyman, Jason M Smith, Ryan J Whitby · 2026
Read Pharmaceutical Innovation and Drug Policy: The Case of the 1984 Hatch-Waxman Act by Benjamin M Blau, Joshua Lyman, Jason M Smith, Ryan J Whitby (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0351859.txt.
Description
Benjamin Blau and three colleagues examine this 2026 PLOS One economics paper on whether a landmark 1984 American drug law changed how much pharmaceutical firms innovate. The Hatch-Waxman Act tried to balance patent protection for new drugs against cheaper generic competition, and a 2003 amendment adjusted the deal again. The authors compared drug industry research spending with other industries before and after each change.
Pharmaceutical research and development rose markedly relative to other industries after the 1984 act took effect. The 2003 amendment showed no such boost and, if anything, was linked to reduced innovation. The authors conclude that drug innovation responds strongly to policy choices that change the expected rewards for developing new medicines.
Catalog record
| CREATOR | Benjamin M Blau, Joshua Lyman, Jason M Smith, Ryan J Whitby |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57287 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |